| Drug ID: | Drug39 |
|---|---|
| Drug Name: | Thalidomide |
| CID: | 5426 |
| DrugBank ID: | DB01041 |
| Modality: | Small Molecule |
| Groups: | approved|investigational|withdrawn |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06382519, , NCT00720538 |
| Molecular Formula: | C13H10N2O4 |
| Molecular Weight: | 258.23 g/mol |
| Isomeric SMILES: | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
| Synonyms: | thalidomide; 50-35-1; Contergan; Distaval; Pantosediv; Softenon; Kevadon; Theophilcholine; Algosediv; Corronarobetin |
| Phase 0: | 2 |
| Phase 1: | 33 |
| Phase 2: | 265 |
| Phase 3: | 97 |
| Phase 4: | 20 |
| Description: | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt355 | 5426 | Thalidomide | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt356 | 5426 | Thalidomide | 2263 | FGFR2 | Homo sapiens (human) | None | |
| dt357 | 5426 | Thalidomide | 7124 | TNF | Homo sapiens (human) | None | |
| dt358 | 5426 | Thalidomide | 8451 | CUL4A | Homo sapiens (human) | Inhibitor | |
| dt359 | 5426 | Thalidomide | 51185 | CRBN | Homo sapiens (human) | 20223979 | Binding |
| dt360 | 5426 | Thalidomide | 2651 | GCNT2 | Mus musculus (house mouse) | 26217789 | Thalidomide results in decreased expression of GCNT2 mRNA |
| dt361 | 5426 | Thalidomide | 2638 | GC | Gallus gallus (chicken) | 28892372 | Thalidomide results in decreased expression of GC mRNA |
| dt362 | 5426 | Thalidomide | 6241 | RRM2 | Homo sapiens (human) | 18720364 | [azacitidine co-treated with thalidomide] affects the expression of RRM2 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06382519 | Thalidomide Therapy for VEOIBD | None | RECRUITING | Children's Hospital of Fudan University | Inflammatory Bowel Diseases | DRUG: Thalidomide | Details |
| NCT00720538 | Thalidomide in Pediatric Inflammatory Bowel Diseases. | PHASE3 | COMPLETED | IRCCS Burlo Garofolo | Inflammatory Bowel Diseases|Crohn's Disease|Ulcer… | DRUG: Thalidomide|DRUG: placebo | Details |
| ISRCTN23541842 | The auxiliary diagnostic value of fissured tongue on axial and peripheral joint dysfunction in Ankylosing Spondylitis | Not Available | Not Recruiting | Zhejiang University Of Chinese Medicine | Ankylosing spondylitis Musculoskeletal Diseases … | Participants are screened and undergo a clinical … | Details |
| EUCTR2005-005414-20-IT | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Not Available | Authorised | ISTITUTO PER L INFANZIA BURLO GAROFOLO | Inflammatory Bowel Disease Crohn Disease, Ulcera… | Trade Name: Thalidomide Pharmion Pharmaceutical F… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
A review of thalidomide and digestive system related diseases
PMID: 40510146
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Thalidomide, once discovered and used to treat pregnancy sickness, fell out of favor with teratogenicity scandals, and then re-entered the public eye…
Exploring the Targets and Molecular Mechanisms of Thalidomide in the Treatment …
PMID: 37961863
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Ulcerative colitis (UC) is a chronic, nonspecific, inflammatory disease of the intestine with an unknown cause. Thalidomide (THA) has bee…
Comparison and development of machine learning for thalidomide-induced peripher…
PMID: 37426324
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Thalidomide is an effective treatment for refractory Crohn's disease (CD). However, thalidomide-induced peripheral neuropathy (TiPN), whi…
Gene expression profiling in white blood cells reveals new insights into the mo…
PMID: 37257228
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Thalidomide has emerged as an effective immunomodulator in the treatment of pediatric patients with inflammatory bowel disease (IBD) refractory to st…
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis…
PMID: 36400133
Year: 2023
Relationship Type:
Treatment
Score: 6.5
High levels of proinflammatory cytokines, macrophage polarization status and immune-mediated angiogenesis play pivotal roles in the pathogenesis of i…
The efficacy and safety of thalidomide in the treatment of refractory Crohn's d…
PMID: 36284737
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Thalidomide is applied in therapy for refractory Crohn's disease (CD) in adults, but systematic and rigorous clinical evidence is scant. …
Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Mac…
PMID: 34085173
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The TNF-alpha inhibitor thalidomide is reported to be effective for indu…
A drug repositioning success: The repositioned therapeutic applications and mec…
PMID: 33249990
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Thalidomide is the most teratogenic human medicine ever marketed and was associated with birth defects in approximately 10,000 children i…
Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2…
PMID: 33206273
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Immune-mediated angiogenesis is important in the pathogenesis of inflammatory bowel disease and targeted treatment could alleviate the disease. Thali…
[Thalidomide in refractory Crohn's disease: long-term efficacy and safety]
PMID: 32486585
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Objective: To analyze the long-term efficacy and safety of thalidomide on refractory Crohn's disease (CD). Methods: A total of 79 patients with refra…
Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for …
PMID: 32298484
Year: 2020
Relationship Type:
Treatment
Score: 6.5
WHAT IS KNOWN AND THE OBJECTIVE: De novo Crohn's disease (CD) is an increasingly reported diagnosis after ileal pouch anal anastomosis (IPAA). Curren…
Thalidomide Prevented and Ameliorated Pathogenesis of Crohn's Disease in Mice v…
PMID: 31920668
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Crohn's disease (CD) is a chronic, relapsing form of inflammatory bowel disease, seriously threatening human health. Thalidomide has been used for th…
Long-term outcomes of thalidomide in pediatric Crohn's disease
PMID: 31758718
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIM: In this largest pediatric cohort to date in Asian population, we aimed to report our long-term real-life experience with thalidom…
Early onset first-episode psychosis during treatment with thalidomide for refra…
PMID: 31174605
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Inflammatory bowel disease and schizophrenia spectrum disorders are complex and multifactorial conditions characterized by great variabil…
Thalidomide-induced sinus bradycardia in Crohn's disease: case report and liter…
PMID: 30832535
Year: 2019
Relationship Type:
Adverse Effect
Score: 6.5
Thalidomide is effective in inducing and maintaining clinical remission, as well as mucosal healing, in patients with refractory Crohn's disease (CD)…
Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of t…
PMID: 29209113
Year: 2017
Relationship Type:
Treatment
Score: 6.3
AIM: To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease (CD) with tuberculosis infection. METHODS: A…
Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Ped…
PMID: 28817461
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Thalidomide is an effective therapy in children with inflammatory bowel disease refractory to standard treatments, but thalidomide-induce…
Thalidomide is a therapeutic agent that is effective in inducing and maintainin…
PMID: 27836485
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIMS: Previous studies have indicated that thalidomide may be effective in achieving clinical remission and response; however, there i…
Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic r…
PMID: 27603389
Year: 2016
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Thalidomide has been successful use in patients with refractory Crohn disease (CD) in recent years. METHODS: We collected the data of a p…
Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents
PMID: 27567409
Year: 2016
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: To characterize the longitudinal clinical and electrophysiological patterns of thalidomide neuropathy in children and adolescents. STUDY D…